However, the number of therapeutic molecules that have been developed against signal transduction proteins
that are involved in protein-protein interactions is increasing at a steady rate.
Kinases: From Targets to Therapeutics reviews the considerable array of inhibitors in development for therapeutics targeting the kinase family of signal transduction proteins
The K-ras oncogene and other farnesylated signal transduction proteins
are considered the gene targets for anti-cancer activity in these tumors, however competitor products have not demonstrated significant anti-tumor activity in these major tumor populations.